Active Pharmaceutical Ingredients (API), popularly speaking, are the raw materials of medicines, only pharmaceutical raw materials are processed into pharmaceutical preparations , can they become medicines available for clinical use, so drugs we usually eat are the finished drugs through processing. Active Pharmaceutical Ingredients based on its sources can be divided into two major categories ,including chemical synthetic drugs and natural chemical drugs. Chemical synthetic drugs can be divided into organic synthetic drugs and inorganic synthetic drugs. Inorganic synthetic drugs are inorganic compounds ( very few is element), such as aluminum hydroxide, magnesium trisilicate which are used for the treatment of gastric and duodenal ulcers ; organic synthetic drugs are mainly composed of drugs made by basic organic chemical raw materials, through a series of organic chemical reactions (such as aspirin, chloramphenicol, caffeine, etc.). Natural chemical drugs ,based on its sources,can be divided into two categories including biochemical drugs and plant chemical drugs. Antibiotics are generally made by the microbial fermentation, which belongs to the biochemistry category. A variety of semi-synthetic antibiotics occurs in recent years,which are biosynthesis and chemical synthesis combining products.Among active Pharmaceutical Ingredients, the organic synthetic drugs varieties, yields and values have the largest proportion,which are the main pillars of the chemical and pharmaceutical industries. The quality of active Pharmaceutical Ingredients decides whether the formulation is good or bad , so its quality standards are very strict ,countries in the world have developed national pharmacopoeia standards and strict quality control methods for its widely used active Pharmaceutical ingredients.
Virginiamycin: Animal Growth Promotion and the Human Health Risk Quandary
Virginiamycin, a streptogramin antibiotic used in animal feed to promote growth, raises concerns about antibiotic resistance despite its benefits.
Oct 13,2025 APICreatine Phosphate Disodium Salt: From Bioenergetic Buffer to Biomedical Applications
Creatine phosphate disodium salt (CPDS) acts as a high-energy phosphate reserve, stabilizes ATP levels and enables hydroxyapatite synthesis.
Oct 13,2025 APID-Tryptophan Methyl Ester Hydrochloride: An Immunomodulator Regulating Tryptophan Metabolism
D-Tryptophan methyl ester hydrochloride, a chiral amino acid derivative, acts as an IDO1 inhibitor and shifts the kynurenine pathway to elevate KYNA.
Oct 13,2025 APIRivastigmine Tartrate: From Mechanism to Long-Term Alzheimer's Care
Rivastigmine tartrate, a dual cholinesterase inhibitor, improves cognition and daily function in Alzheimer's patients via a P450-independent pathway.
Oct 13,2025 API2,3,5-Triphenyltetrazolium Chloride: A Versatile Dye for Tissue Vitality Detection and Ablated Area Evaluation
2,3,5-Triphenyltetrazolium chloride identifies brain infarction, evaluates IRE ablation, and improves brain staining via mannitol-facilitated perfusion.
Oct 13,2025 APIPotassium chloroplatinate: Composite Film Behavior
Potassium chloroplatinate influences dielectric properties and ionic conductivity, showing Arrhenius-like behavior with minimum activation.
Oct 10,2025 APISunifiram: A Potent Nootropic Agent Targeting Cognitive Enhancement
Sunifiram, a potent nootropic stronger than piracetam, improves cognition in animal models by targeting NMDAR glycine sites and cholinergic systems.
Oct 9,2025 APIMethyl 3,4,5-Trimethoxybenzoate: A Versatile Molecule as Membrane-Active Anticancer Agents
Methyl 3,4,5-trimethoxybenzoate interacts strongly with cell membranes, demonstrating potent antiproliferative activity against cancer cells.
Sep 30,2025 API4-Chlorodehydromethyltestosterone: From Development and Abuse to Advanced Detection Strategies
4-Chlorodehydromethyltestosterone is a banned steroid with a complex metabolism and detection strategies using GC-MS/MS have identified long-term metabolites.
Sep 30,2025 APIRepotrectinib: A New Anti-cancer Drug
Repotrectinib is an oral inhibitor of ROS1, and it represents the first approved targeted therapy that specifically includes patients previously treated with a ROS1 TKI in FDA labeling.
Sep 29,2025 API